US Patent 7846973 Chemical process and new crystalline form
Patent 7846973 was granted and assigned to Theravance on December, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+205 characters)
Article
Patent abstract
The present invention relates to the preparation of a β2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I)
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Darren Michael Caine0
Ian Leonard Paternoster0
Peter David Penberthy Shapland0
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07846973 Chemical process and new crystalline form US Patent 7846973 Chemical process and new crystalline form
Infobox
Patent Number
07846973
Patent Number
7846973
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07846973 Chemical process and new crystalline form
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07846973
Date of patent
December 7, 2010
Patent application number
10599145
Date Filed
March 30, 2005
Patent primary examiner
Find more entities like US Patent 7846973 Chemical process and new crystalline form
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
